Intranasal steroids and the risk of emergency department visits for asthma.

BACKGROUND In patients with asthma, treatment for associated conditions, such as rhinitis, is recommended. It is unknown whether this treatment can reduce the risk for emergency department (ED) visits for asthma. OBJECTIVES We sought to determine whether treatment with intranasal steroids or prescription antihistamines in persons with asthma is associated with a reduced risk for ED visits caused by asthma. METHODS We performed a retrospective cohort study of members of a managed care organization aged greater than 5 years who were identified during the period of October 1991 to September 1994 as having a diagnosis of asthma by using a computerized medical record system. The main outcome measure was an ED visit for asthma. RESULTS Of the 13,844 eligible persons, 1031 (7.4%) had an ED visit for asthma. The overall relative risk (RR) for an ED visit among those who received intranasal corticosteroids, adjusted for age, sex, frequency of orally inhaled corticosteroid and beta-agonist dispensing, amount and type of ambulatory care for asthma, and diagnosis of an upper airways condition (rhinitis, sinusitis, or otitis media), was 0.7 (95% confidence interval [CI], 0.59-0.94). For those receiving prescription antihistamines, the risk was indeterminate (RR, 0.9; 95% CI, 0.78-1.11). When different rates of dispensing for intranasal steroids were examined, a reduced risk was seen in ED visits in those with greater than 0 to 1 (RR, 0.7; 95% CI, 0.57-0.99) and greater than 3 (RR, 0.5; 95% CI, 0.23-1.05) dispensed prescriptions per year. CONCLUSIONS Treatment of nasal conditions, particularly with intranasal steroids, confers significant protection against exacerbations of asthma leading to ED visits for asthma. These results support the use of intranasal steroids by individuals with asthma and upper airways conditions.

[1]  R. Hubbard,et al.  Inhaled corticosteroid use and bone-mineral density in patients with asthma , 2000, The Lancet.

[2]  R. Naclerio,et al.  As-needed use of fluticasone propionate nasal spray reduces symptoms of seasonal allergic rhinitis. , 2000, The Journal of allergy and clinical immunology.

[3]  E. Meltzer,et al.  Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. , 2000, Pediatrics.

[4]  K. Nolop,et al.  Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. , 2000, Pediatrics.

[5]  D. Nash,et al.  Optimizing quality of care and cost effectiveness in treating allergic rhinitis in a managed care setting. , 2000, The American journal of managed care.

[6]  F. Leone,et al.  Pharmaceutically-based severity stratification of an asthmatic population. , 1999, Respiratory medicine.

[7]  J. Corren.  Intranasal corticosteroids for allergic rhinitis: how do different agents compare? , 1999, The Journal of allergy and clinical immunology.

[8]  W. Lumry.  A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. , 1999, The Journal of allergy and clinical immunology.

[9]  F. Simons,et al.  Allergic rhinobronchitis: the asthma-allergic rhinitis link. , 1999, The Journal of allergy and clinical immunology.

[10]  J. Bousquet,et al.  Perennial rhinitis: An independent risk factor for asthma in nonatopic subjects: results from the European Community Respiratory Health Survey. , 1999, The Journal of allergy and clinical immunology.

[11]  M. Cifaldi,et al.  Targeted intervention programs: creating a customized practice model to improve the treatment of allergic rhinitis in a managed care population. , 1999, The American journal of managed care.

[12]  A. Togias,et al.  Rhinitis is ubiquitous in allergic asthmatics. , 1999 .

[13]  C E Reed,et al.  Allergic rhinitis in Rochester, Minnesota residents with asthma: frequency and impact on health care charges. , 1999, The Journal of allergy and clinical immunology.

[14]  B. Lundbäck,et al.  Epidemiology of rhinitis and asthma. , 1998, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[15]  W. Crawford,et al.  Comparative Efficacy of Terfenadine, Loratadine, and Astemizole in Perennial Allergic Rhinitis , 1998, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[16]  A. Harris,et al.  Efficacy and safety of loratadine plus pseudoephedrine in patients with seasonal allergic rhinitis and mild asthma. , 1997, The Journal of allergy and clinical immunology.

[17]  Third Expert Panel on theDiagnosis,et al.  Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma , 1997 .

[18]  S. Weiss,et al.  Inhaled steroids and the risk of hospitalization for asthma. , 1997, JAMA.

[19]  J. Corren.  Allergic rhinitis and asthma: how important is the link? , 1997, The Journal of allergy and clinical immunology.

[20]  S. Spector.  Overview of comorbid associations of allergic rhinitis. , 1997, The Journal of allergy and clinical immunology.

[21]  P. Cauwenberge.  Diagnosis in rhinitis coexisting with asthma , 1997 .

[22]  G. Canonica,et al.  Increase of asthma and allergic rhinitis prevalence in young Italian men. , 1996, International archives of allergy and immunology.

[23]  A. Foresi,et al.  Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and inflammation but also attenuates the increase in bronchial responsiveness during the pollen season in allergic rhinitis. , 1996, The Journal of allergy and clinical immunology.

[24]  C. Comer,et al.  Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis. , 1996, The Journal of allergy and clinical immunology.

[25]  G. Settipane,et al.  Cetirizine in patients with seasonal rhinitis and concomitant asthma: prospective, randomized, placebo-controlled trial. , 1995, The Journal of allergy and clinical immunology.

[26]  C. Bucca,et al.  Extrathoracic and intrathoracic airway responsiveness in sinusitis. , 1995, The Journal of allergy and clinical immunology.

[27]  W. Morgan,et al.  Epidemiology of physician-diagnosed allergic rhinitis in childhood. , 1994, Pediatrics.

[28]  S. Suissa,et al.  Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. , 1994, The European respiratory journal.

[29]  T. Platts-Mills,et al.  Chronic sinusitis. Relationship of computed tomographic findings to allergy, asthma, and eosinophilia. , 1994, JAMA.

[30]  F. Simons,et al.  Treatment of allergic rhinitis with intranasal corticosteroids in patients with mild asthma: effect on lower airway responsiveness. , 1993, The Journal of allergy and clinical immunology.

[31]  J. E. Gamble,et al.  Otitis Media and Chronic Middle Ear Effusion in the Asthmatic Pediatric Patient , 1992, Ear, nose, & throat journal.

[32]  C. Irvin,et al.  Nasal beclomethasone prevents the seasonal increase in bronchial responsiveness in patients with allergic rhinitis and asthma. , 1992, The Journal of allergy and clinical immunology.

[33]  F. Neukirch,et al.  Different effects of nasal and bronchial glucocorticosteroid administration on bronchial hyperresponsiveness in patients with allergic rhinitis. , 1992, The American review of respiratory disease.

[34]  J. Bernstein.  The role of IgE-mediated hypersensitivity in the development of otitis media with effusion. , 1992, Otolaryngologic clinics of North America.

[35]  P. Fireman.  The role of antihistamines in otitis. , 1990, The Journal of allergy and clinical immunology.

[36]  R. Dahl,et al.  Nasal inhalation of the glucocorticoid budesonide from a spacer for the treatment of patients with pollen rhinitis and asthma , 1990, Allergy.

[37]  S. Savolainen.  Allergy in patients with acute maxillary sinusitis , 1989, Allergy.

[38]  Y. Kurono,et al.  The role of nasal allergy in otitis media with effusion. A clinical study. , 1988, Acta oto-laryngologica. Supplementum.

[39]  J. Naessens,et al.  Efficacy of beclomethasone nasal solution, flunisolide, and cromolyn in relieving symptoms of ragweed allergy. , 1987, Mayo Clinic proceedings.

[40]  W. Doyle,et al.  Eustachian tube obstruction (ETO) after histamine nasal provocation--a double-blind dose-response study. , 1987, The Journal of allergy and clinical immunology.

[41]  J. Bernstein,et al.  Further Observations on the Role of IgE-Mediated Hypersensitivity in Recurrent Otitis Media with Effusion , 1985, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[42]  O S Miettinen,et al.  Post-marketing studies of drug efficacy: why? , 1984, The American journal of medicine.

[43]  A. Wenzel,et al.  Effect of an intranasally administered corticosteroid (budesonide) on nasal obstruction, mouth breathing, and asthma. , 2015, American Review of Respiratory Disease.

[44]  E. Baráth,et al.  Fundamentals of Biostatistics. , 1992 .

[45]  D. Webb,et al.  Allergic and nonallergic rhinitis: their characterization with attention to the meaning of nasal eosinophilia. , 1980, The Journal of allergy and clinical immunology.